David Chang
2021
In 2021, David Chang earned a total compensation of $10.2M as President and Chief Executive Officer at Allogene Therapeutics, a 30% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $396,150 |
|---|---|
| Option Awards | $6,352,635 |
| Salary | $695,000 |
| Stock Awards | $2,717,669 |
| Total | $10,161,454 |
Chang received $6.4M in option awards, accounting for 63% of the total pay in 2021.
Chang also received $396.2K in non-equity incentive plan, $695K in salary and $2.7M in stock awards.
Rankings
In 2021, David Chang's compensation ranked 1,018th out of 12,415 executives tracked by ExecPay. In other words, Chang earned more than 91.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,018 out of 12,415 | 92nd |
Division Manufacturing | 344 out of 5,505 | 94th |
Major group Chemicals And Allied Products | 116 out of 2,375 | 95th |
Industry group Drugs | 99 out of 2,096 | 95th |
Industry Biological Products, Except Diagnostic Substances | 29 out of 449 | 94th |
Source: SEC filing on April 26, 2022.
Chang's colleagues
We found four more compensation records of executives who worked with David Chang at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019